Clinical Trials Browser

Recurrence × pomalidomide × 1 year × Clear all

NCT06615479 2026-04-14

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT05455320 2026-04-13

MonumenTAL-3

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05572515 2026-04-13

MajesTEC-9

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05519085 2026-03-24

SUCCESSOR-1

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT01562405 2026-01-14

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT05922501 2026-01-14

ISABELA

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT07312188 2025-12-31

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT05911321 2025-10-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT04176718 2025-10-07

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT07018050 2025-09-22

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT04191616 2025-09-04

SELECT

Phase 2 Completed

54 enrolled 17 charts

Multiple Myeloma, Recurrence

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Multiple Myeloma, Recurrence

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Phase 3 Active not recruiting

Multiple Myeloma, Neoplasms, Recurrence